Alentis Therapeutics has secured $181.4 million in an oversubscribed Series D financing round to advance its antibody-drug conjugates targeting claudin-1 (CLDN1)-positive tumors and organ fibrosis. This funding, led by OrbiMed and supported by several investors, brings the total raised by the company to $366.4 million since its founding in 2018. Clinical data for its innovative therapies is expected within the next 12 to 18 months.
Kivu Biosciences, a San Francisco biotech startup, has raised $92 million in a Series A funding round to develop advanced antibody-drug conjugates (ADCs) aimed at improving precision and stability while reducing side effects. The company plans to initiate its first clinical trial targeting solid tumors next year, utilizing proprietary technology from Synaffix to enhance drug delivery. Kivu's approach seeks to address the limitations of existing ADCs, focusing on a better benefit-to-risk ratio for cancer patients.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
